This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority of Dupixent® (dupilumab) over Xolair® (omalizumab) in a first-of-its-kind, head-to-head, Phase 4 study in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and co-existing asth
Zilucoplan CAS 1841136-73-9 YG391PK0CC, RA101495, WHO 10602 3562 g/mol, C 172 H 278 N 24 O 55 Zilucoplan lso designated as RA101495, is the active principle of Zilbrysq ® , commercialized by UCB Pharma S.A. It is a 3.5 kDa synthetic macrocyclic peptide composed of 15 amino acid residues, including four unnatural amino acids [ 27 ]. The amino acid residues composition is: L-Lys, L-Val, L-Glu, L-Arg, L-Phe, L-Asp, L-L-NMe-Asp, L-tButyl-Gly, L-Tyr, L-7-aza-Trp, L-Glu, L-Tyr, L-Pro, L-Cyclohexyl-Gly
QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at improving the standard of care for patients battling myeloproliferative neoplasms (MPNs) — a group of rare but serious blood disorders — by developing a novel, multimodal diagnostic panel designed to aid clinician decision-making and enable the delivery of more persona
Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2 EPCORE® NHL-2 trial (Arm 10, NCT04663347) evaluating its T-cell-engaging bispecific antibody, epcoritamab, in combination with rituximab, ifosfamide, carboplatin, and etoposide — a regimen collectively known as R-ICE — in adult patients with relapsed or refractory (R/R) diffuse large B-cel
SUNDAY, June 15, 2025 — Struggling to get a good night’s sleep? A new study suggests that a natural solution might be found right in your fridge: fruits and veggies. Researchers from the University of Chicago and Columbia University.
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S. Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD).
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S. Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD).
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated and extensive follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study evaluating lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002) in patients with hereditary angioedema (HAE).
Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of its benefit-risk profile in non-ambulatory patients with Duchenne muscular dystrophy (DMD). This update comes after two cases of fatal acute liver failure (ALF) were reported in non-ambulatory DMD patients who received Elevidys, a phenomenon that underscores the ongo
Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) — two first-in-class, FDA-approved bispecific antibodies — in patients battling triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) wi
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content